Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major public health concern in Latin America, where prevalence exceeds 40%. A high frequency of genetic risk variants, particularly the PNPLA3 risk allele, contributes to greater disease prevalence and severity across the region. Fragmented health systems, shortages of trained personnel, and limited access to advanced noninvasive diagnostic tools and emerging pharmacotherapies constrain MASLD effective care in the region. These structural barriers highlight the need for coordinated public health strategies to expand screening, strengthen diagnostic capacity, and improve equitable access to treatment. This review summarizes regional epidemiology, diagnostic gaps, and health system priorities for addressing MASLD in Latin America.